NASDAQ:BIOL - BIOLASE Stock Price, Forecast & News

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

BIOLASE's stock reverse split on Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split.

BIOLASE Inc (NASDAQ:BIOL) announced its quarterly earnings data on Wednesday, November, 6th. The medical technology company reported ($0.12) EPS for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.13. The medical technology company had revenue of $8.65 million for the quarter. BIOLASE had a negative return on equity of 313.64% and a negative net margin of 52.13%. View BIOLASE's Earnings History.

BIOLASE is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for BIOLASE.

4 Wall Street analysts have issued 1 year price targets for BIOLASE's shares. Their forecasts range from $2.00 to $3.00. On average, they anticipate BIOLASE's stock price to reach $2.50 in the next year. This suggests a possible upside of 220.5% from the stock's current price. View Analyst Price Targets for BIOLASE.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOLASE.

Press coverage about BIOL stock has been trending somewhat negative this week, InfoTrie reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. BIOLASE earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave news headlines about the medical technology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for BIOLASE.

Some companies that are related to BIOLASE include Straumann (SAUHF), DENTSPLY SIRONA (XRAY), Sartorius (SARTF), SmileDirectClub (SDC), Biomerica (BMRA) and Remedent (REMI).

Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Magnachip Semiconductor (MX), Fluidigm (FLDM), NovaBay Pharmaceuticals (NBY), Vuzix (VUZI), Athersys (ATHX), Allena Pharmaceuticals (ALNA), CTI BioPharma (CTIC) and LivePerson (LPSN).

Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BIOL stock can currently be purchased for approximately $0.78.

BIOLASE has a market capitalization of $24.14 million and generates $46.15 million in revenue each year. The medical technology company earns $-21,520,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. BIOLASE employs 190 workers across the globe.View Additional Information About BIOLASE.

The official website for BIOLASE is http://www.biolase.com/.

BIOLASE's mailing address is 4 Cromwell, Irvine CA, 92618. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected]